Skip to main content
SpringerLink
Log in

Mitotane

  • Chapter
  • First Online:
Adrenocortical Carcinoma

  • 635 Accesses

Abstract

Mitotane (o,p’-DDD), an analog of the insecticide DDT, has been used for the treatment of advanced adrenocortical carcinoma (ACC) since the 1960s. Its use as an adjunctive postoperative measure remained more controversial. Despite being in use for many years, the rarity of ACC precluded the organization of randomized trials; thus many areas of uncertainty and controversy remain regarding the role of this old drug in the clinical management of patients with ACC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6(4):386–394

    CAS  PubMed  Google Scholar 

  2. Schteingart DE et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 667–680

    Article  Google Scholar 

  3. MICROMEDEX® Healthcare Series, Copyright © 1974–2009, Thomson Reuters

    Google Scholar 

  4. Schteingart DE (2000) Conventional and novel strategies in the treatment of adrenocortical cancer. Brazilian J Med Biol Res 33:1197–1200

    CAS  Google Scholar 

  5. Hart MM et al (1973) The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 24: 127–159

    Article  Google Scholar 

  6. Cueto C, Brown JH (1958) The chemical fractionation of an adrenocorticolytic drug. Endocrinology 62:326–333

    Article  CAS  PubMed  Google Scholar 

  7. Nelson AA, Woodard G (1949) Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 48:387–394

    CAS  Google Scholar 

  8. Nichols J, Hennigar G (1957) Studies on DDD, 2,2-bis (parachlorophenyl)-1,1-dichloroethane. Exp Med Surg 15:310–316

    CAS  PubMed  Google Scholar 

  9. Kaminsky N et al (1962) Ultrastructure of adrenal cortex of the dog during treatment with DDD. J Natl Cancer Inst 29:127–159

    CAS  PubMed  Google Scholar 

  10. Vilar O, Tullner WW (1959) Effects of o,p’DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 65:80–86

    Article  CAS  PubMed  Google Scholar 

  11. Bergenstal DM et al (1960) Chemotherapy of adrenocortical cancer with o,p’DDD. Ann Intern Med 53:672

    CAS  Google Scholar 

  12. Hutter AM Jr, Kayhoe DE (1966) Adrenal cortical carcinoma: clinical features in 138 patients. Am J Med 41:572–580

    Article  PubMed  Google Scholar 

  13. Lubitz JA et al (1973 Mar 5) Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 223(10):1109–1112

    Article  CAS  PubMed  Google Scholar 

  14. Hoffman DL, Mattox VR (1972 Jul) Treatment of adrenocortical carcinoma with o,p’-DDD. Med Clin North Am 56(4):999–1012

    CAS  PubMed  Google Scholar 

  15. Boven E et al (1984) Complete response of metastatized adrenal cortical carcinoma with op’-DDD. Case report and literature review. Cancer 53: 26–29

    Article  CAS  PubMed  Google Scholar 

  16. Wooten MD, King DK (1993) Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72(11): 3145–3155

    Article  CAS  PubMed  Google Scholar 

  17. WHO handbook for reporting results of cancer treatment WHO Offset Publication No 48. Geneva, 1979

    Google Scholar 

  18. Dackiw AP et al (2001) Adrenal cortical carcinoma. World J Surg 25:914–926

    Article  CAS  PubMed  Google Scholar 

  19. Vassilopoulou-Sellin R et al (1993) Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71(10): 3119–3123

    Article  CAS  PubMed  Google Scholar 

  20. Wajchenberg B et al (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88:711–736

    Article  CAS  PubMed  Google Scholar 

  21. Decker RA et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6):1006–1013

    CAS  PubMed  Google Scholar 

  22. Hajiar RA et al (1975) Adrenal cortical carcinoma: a study of 32 patients. Cancer 35: 549–554

    Article  Google Scholar 

  23. Haq MM et al (1980) Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64: 909–913

    CAS  PubMed  Google Scholar 

  24. Hogan TF et al (1978) op’,DDD (mitotane) therapy for adrenal cortical carcinoma: observation on drug dosage, toxicity, and steroid replacement. Cancer 42: 2177–2181

    Article  CAS  PubMed  Google Scholar 

  25. Venkatesh S et al (1989) Adrenal cortical carcinoma. Cancer 64: 765–769

    Article  CAS  PubMed  Google Scholar 

  26. Grapski RT et al (1983) Cisplatin chemotherapy of adrenocortical carcinoma. Proc Am Soc Clin Oncol 2: 232

    Google Scholar 

  27. Luton JP et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195–2001

    Article  CAS  PubMed  Google Scholar 

  28. Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112: 963–970

    CAS  PubMed  Google Scholar 

  29. Tattersall MH et al (1980) Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1:419–421

    CAS  PubMed  Google Scholar 

  30. Bodie B et al (1989) The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 141:257–260

    CAS  PubMed  Google Scholar 

  31. Williamson SK et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88(5): 1159–1165

    Article  CAS  PubMed  Google Scholar 

  32. Haak HR et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947–951

    Article  CAS  PubMed  Google Scholar 

  33. Van Slooten H et al (1984) The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47–53

    Article  PubMed  Google Scholar 

  34. Baudin E et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385–1392

    Article  CAS  PubMed  Google Scholar 

  35. Seki M et al (1999) Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer 6:529–533

    Article  CAS  PubMed  Google Scholar 

  36. Allolio B, Fassnacht M (2006) Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027–2037

    Article  CAS  PubMed  Google Scholar 

  37. Bates SE et al (1991) Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/Pglycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73(1): 18–29

    Article  PubMed  Google Scholar 

  38. Villa R et al (1999) Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 14(1):133–138

    CAS  PubMed  Google Scholar 

  39. Abraham J et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9): 2333–2343

    Article  CAS  PubMed  Google Scholar 

  40. Faggiano A et al (2006) Rapidly progressing high o,p’DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol 64:110–113

    Article  CAS  Google Scholar 

  41. Terzolo M et al (2000) Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer J Clin Endocrin Metab 86 (6): 2234–2238

    Google Scholar 

  42. Daffara F et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043–1053

    Article  CAS  PubMed  Google Scholar 

  43. Hague RV et al (1989) Hepatic microsomal enzyme induction and adrenal crisis due to o,p’DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol 31:51–57

    Article  CAS  Google Scholar 

  44. Kasperlik-Zaluska AA (2000) Clinical results of the use of mitotane for adrenocortical carcinoma. Brazilian J Med Biol Res 33:1191–1196

    CAS  Google Scholar 

  45. Nader N et al (2006) Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 91:2165–2170

    Article  CAS  PubMed  Google Scholar 

  46. Allolio B et al (2004) Management of adrenocortical carcinoma. Clin Endocrinol 60:273–287

    Article  Google Scholar 

  47. Icard P et al (1992) Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112: 972–980

    CAS  PubMed  Google Scholar 

  48. Kasperlik-Zaluska AA et al (1995) Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75: 2587–2591

    Article  CAS  PubMed  Google Scholar 

  49. Dickstein G et al (1998) Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 83:3100–3103

    Article  CAS  PubMed  Google Scholar 

  50. Schteingart DE et al (1982 Sep) Treatment of adrenal carcinomas. Arch Surg 117(9):1142–1146

    CAS  PubMed  Google Scholar 

  51. Barzon L et al (1999 Apr) Comment – Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 84(4):1488–1489

    Article  CAS  PubMed  Google Scholar 

  52. Barzon L et al (1997 Nov–Dec) Adrenocortical carcinoma: experience in 45 patients. Oncology 54(6):490–496

    Article  CAS  PubMed  Google Scholar 

  53. Icard P et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25: 891–897

    Article  CAS  PubMed  Google Scholar 

  54. Terzolo M (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372–2380

    Article  CAS  PubMed  Google Scholar 

  55. Bertherat J et al (2007) Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N Engl J Med 357:1256–1257

    Article  CAS  PubMed  Google Scholar 

  56. Abiven G et al (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650–2655

    Article  CAS  PubMed  Google Scholar 

  57. Terzolo M et al (2007) Adjuvant mitotane in adrenocortical carcinoma. Letter to the editor. N Engl J Med 357:1259

    CAS  Google Scholar 

  58. Schteingart DE (2007) Adjuvant Mitotane Therapy of Adrenal Cancer – Use and Controversy. N Engl J Med 356:2415–2418

    Article  CAS  PubMed  Google Scholar 

  59. Lee JE (2007) Adjuvant mitotane in adrenocortical carcinoma. Letter to the Editor. N Engl J Med 357:1256–1258

    Article  Google Scholar 

  60. Stojadinovic A et al (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20:941–950

    Article  CAS  PubMed  Google Scholar 

  61. Dickstein G et al (2007) Adjuvant Mitotane in Adrenocortical Carcinoma. Letter to the Editor. N Engl J Med 357(12):1257

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Biological Sciences, Medicina Interna 1, AOU San Luigi Gonzaga, University of Turin, Regione Gonzole, 10, 10043, Orbassano, Italy

    Massimo Terzolo, Arianna Ardito, Barbara Zaggia & Fulvia Daffara

  2. Department of Clinical and Biological Sciences, Farmacologia, AOU San Luigi Gonzaga, University of Turin, Regione Gonzole, 10, 10043, Orbassano, Italy

    Silvia De Francia

Authors
  1. Massimo Terzolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arianna Ardito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Zaggia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia De Francia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fulvia Daffara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Terzolo .

Editor information

Editors and Affiliations

  1. Zina Pitcher Place 109, Ann Arbor, 48109-2200, Michigan, USA

    Gary D. Hammer

  2. Dept. Internal Medicine, Div. Pulmonary & Critical Care Medicine, University of Michigan Health System, Zina Pitcher Place 109, Ann Arbor, 48109-2200, Michigan, USA

    Tobias Else

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Terzolo, M., Ardito, A., Zaggia, B., De Francia, S., Daffara, F. (2009). Mitotane. In: Hammer, G., Else, T. (eds) Adrenocortical Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77236-3_22

Download citation

Publish with us

Policies and ethics

Search

Navigation